The 'Prompt-to-Drug' concept isn't just faster drug discovery; it's a seismic shift threatening the entire structure of pharmaceutical R&D.
Forget insulin resistance. The latest breakthrough in Type 2 diabetes treatment reveals a shocking link to immune modulation, changing the entire therapeutic landscape.
Madrigal's massive siRNA licensing deal signals a dangerous consolidation in the MASH drug race. The real winner isn't the patient.
The new Medicare drug price negotiation list isn't about saving seniors money; it’s a calculated political strike against Big Pharma.
New research pairs a cannabis compound with an anti-inflammatory, signaling a massive shift in Alzheimer’s prevention strategy.
Is the fusion of AI and translational science in ALS care a miracle, or a calculated move for data dominance? We dissect the hidden costs.
The convergence of healthcare and artificial intelligence isn't just hype; it's a seismic shift threatening incumbents. Discover the hidden winners in the new pharma landscape.
New cellular imaging is hailed as a breakthrough, but the real story behind this **drug response technology** is who controls the data pipeline.
A new fluorescent technology promises drug response tracking, but the real story is about Big Pharma's control over clinical trial visibility.
The new map of biomedical translational science isn't about progress; it's about control. Discover who's truly winning in the science-to-market race.
The appointment at Health Data Research Service signals a massive power shift in UK medical innovation. Who truly controls your genome?
Beyond the headlines of new fungal compounds and golden sharks, the real story in 'this week in science' is about biotech hype vs. clinical reality.